Alexion Pharmaceuticals (ALXN) Tops Q2 Views; Guides Higher
More News related to ALXN
- Alexion to Present at the 27th Annual JP Morgan Healthcare Conference
- Alexion Pharmaceuticals (ALXN) and PDL BioPharma (PDLI) Resolve Patent Dispute
- Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
- Thomas Weisel Starts Alexion Pharmaceuticals (ALXN) at Overweight
- Alexion's (ALXN) Soliris(R) Observed to Reduce Blood Measures Related to PNH
More News related to Earnings
- DA Davidson Downgrades Cascade (CAE) to Underperform
- BMO Downgrades F5 Networks (FFIV) to Market Perform
- Sterne Agee Downgrades EZCorp (EZPW) to Neutral
- CL King Downgrades Steven Madden (SHOO) to Neutral
- Fox-Pitt Downgrades CastlePoint Holdings (CPHL) to In Line
Alexion Pharmaceuticals (Nasdaq: ALXN) reports Q2 earnings of $0.06 per share, above the consensus of a $0.14 loss. Revenues came in at $59.6 million versus the consensus of $54 million.
Sees $235-$245 million versus prior guidance of $215-$225 million and the consensus of $228.4 million.
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
-1.13Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
